MSL Engagements Related to On-Label Data

STUDY OVERVIEW

As the role of Medical Science Liaisons (MSLs) continues to evolve, pharma companies must continuously re-evaluate and update their guidelines for scientific interactions with Healthcare Practitioners (HCPs) and thought-leaders.

Best Practices conducted this study to provide Medical leaders with insights, as well as the oversight that such engagements occur in a compliant manner. 

KEY TOPICS

• Study Overview
• MSL Engagements
• Auditing MSL Engagements)
  

• How are MSLs allowed to address thought-leaders with regards to product-related on-label data (i.e. pivotal data in the package insert)?
• In regards to the current health crisis surrounding COVID-19, can MSLs proactively (not product related) go to their HCPs and discuss ways to engage virtually?
• How often does your company conduct internal audits in regards to how MSLs engage with thought-leaders?
• Who conducts such audits in your company?
• On what systems or files (such as Veeva, etc.) are you conducting audits of thought-leader engagements?

• Nearly 80% of companies allow MSLs to speak both proactively and reactively to HCPs regarding on-label data. There is little difference in this regards, whether the MSL is in U.S., Europe or other regions of the world.

Best Practices, LLC engaged 23 leaders from 14 life sciences companies through a benchmarking survey. 74% are for either global groups or those representing specific regions or countries outside the U.S.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.